Related Experiment Video
Updated: Jun 23, 2026
05:32
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
Romiplostim: a novel thrombopoiesis-stimulating agent
Sarah Perreault1, Julianna Burzynski
1Department of Pharmacy, Mayo Clinic, Rochester, MN 55901, USA. perreault.sarah@mayo.edu
Summary
Romiplostim effectively increases platelet counts in chronic immune thrombocytopenic purpura (ITP) patients. This thrombopoietic agent stimulates platelet production with manageable side effects, offering a new option for non-responsive cases.
Area of Science:
- Pharmacology and Therapeutics
- Hematology
Background:
- Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts.
- Existing treatments for ITP may have limited efficacy or significant side effects.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, dosage, administration, efficacy, safety, quality of life effects, and therapeutic role of romiplostim.
- To evaluate romiplostim as a second-generation thrombopoietic agent for chronic ITP.
Main Methods:
- Review of clinical trial data and scientific literature on romiplostim.
- Analysis of romiplostim's mechanism of action, clinical efficacy in ITP patients, and safety profile.
Main Results:
- Romiplostim, a peptibody, stimulates the thrombopoietin receptor to increase platelet production without inducing autoantibodies.
- Clinical trials demonstrated increased platelet counts with romiplostim compared to placebo in adult ITP patients.
- Common adverse events included ecchymosis, headache, and petechiae; most were mild to moderate.
Conclusions:
- Romiplostim is a novel thrombopoietic agent for chronic ITP patients unresponsive to other therapies.
- It offers a unique mechanism of action, minimizing the risk of autoantibody formation.
- Potential risks include bone marrow fibrosis, malignancy, thrombosis, and severe thrombocytopenia.
Related Concept Videos
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
01:21Hematopoiesis
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...